PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 228 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.97 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $14,153,391 | -36.9% | 461,323 | -17.5% | 0.00% | -50.0% |
Q2 2023 | $22,413,395 | +3.4% | 559,356 | +5.3% | 0.00% | 0.0% |
Q1 2023 | $21,683,619 | +27.8% | 531,331 | +20.9% | 0.00% | 0.0% |
Q4 2022 | $16,964,076 | -20.6% | 439,370 | +9.4% | 0.00% | -33.3% |
Q3 2022 | $21,371,000 | -14.5% | 401,788 | -6.2% | 0.00% | 0.0% |
Q2 2022 | $24,984,000 | +16.1% | 428,530 | +51.9% | 0.00% | 0.0% |
Q1 2022 | $21,527,000 | +50.2% | 282,074 | +18.4% | 0.00% | +50.0% |
Q4 2021 | $14,330,000 | +1.7% | 238,152 | -5.4% | 0.00% | 0.0% |
Q3 2021 | $14,094,000 | -45.2% | 251,685 | -40.6% | 0.00% | -33.3% |
Q2 2021 | $25,698,000 | +29.9% | 423,504 | +50.1% | 0.00% | 0.0% |
Q1 2021 | $19,778,000 | +43.2% | 282,195 | +22.2% | 0.00% | +50.0% |
Q4 2020 | $13,815,000 | +17.2% | 230,850 | +17.7% | 0.00% | 0.0% |
Q3 2020 | $11,787,000 | +73.6% | 196,067 | +51.5% | 0.00% | 0.0% |
Q2 2020 | $6,791,000 | +32.2% | 129,427 | -15.5% | 0.00% | +100.0% |
Q1 2020 | $5,137,000 | -54.1% | 153,179 | -38.0% | 0.00% | -66.7% |
Q4 2019 | $11,191,000 | +72.6% | 247,042 | +45.1% | 0.00% | +50.0% |
Q3 2019 | $6,484,000 | +459.4% | 170,297 | +538.7% | 0.00% | – |
Q2 2019 | $1,159,000 | +6.0% | 26,664 | -7.2% | 0.00% | – |
Q1 2019 | $1,093,000 | -90.2% | 28,719 | -88.9% | 0.00% | -100.0% |
Q4 2018 | $11,162,000 | -17.6% | 259,470 | -5.9% | 0.00% | 0.0% |
Q3 2018 | $13,554,000 | +288.5% | 275,769 | +153.4% | 0.00% | +200.0% |
Q2 2018 | $3,489,000 | -15.1% | 108,836 | -17.5% | 0.00% | 0.0% |
Q1 2018 | $4,110,000 | -25.9% | 131,948 | +8.7% | 0.00% | -50.0% |
Q4 2017 | $5,544,000 | +57.0% | 121,423 | +29.1% | 0.00% | +100.0% |
Q3 2017 | $3,531,000 | -58.7% | 94,034 | -47.5% | 0.00% | -66.7% |
Q2 2017 | $8,545,000 | +6.3% | 179,140 | +1.6% | 0.00% | +200.0% |
Q1 2017 | $8,040,000 | +3.2% | 176,304 | -26.9% | 0.00% | 0.0% |
Q4 2016 | $7,788,000 | +106.2% | 241,136 | +118.5% | 0.00% | 0.0% |
Q3 2016 | $3,776,000 | -68.6% | 110,347 | -69.0% | 0.00% | -75.0% |
Q2 2016 | $12,017,000 | +277.9% | 356,266 | +493.5% | 0.00% | +300.0% |
Q1 2016 | $3,180,000 | -65.7% | 60,026 | -50.2% | 0.00% | -66.7% |
Q4 2015 | $9,261,000 | +140.4% | 120,614 | +28.7% | 0.00% | +200.0% |
Q3 2015 | $3,853,000 | -15.6% | 93,749 | +45.2% | 0.00% | -50.0% |
Q2 2015 | $4,567,000 | -32.7% | 64,583 | -15.5% | 0.00% | -33.3% |
Q1 2015 | $6,789,000 | -50.3% | 76,410 | -50.4% | 0.00% | -40.0% |
Q4 2014 | $13,654,000 | +42.4% | 153,996 | +55.6% | 0.01% | +25.0% |
Q3 2014 | $9,591,000 | +139.4% | 98,961 | +126.9% | 0.00% | +100.0% |
Q2 2014 | $4,006,000 | -45.4% | 43,612 | -58.4% | 0.00% | -33.3% |
Q1 2014 | $7,341,000 | +350.9% | 104,871 | +270.3% | 0.00% | +200.0% |
Q4 2013 | $1,628,000 | -6.4% | 28,318 | -21.7% | 0.00% | 0.0% |
Q3 2013 | $1,739,000 | +113.6% | 36,169 | +28.8% | 0.00% | – |
Q2 2013 | $814,000 | – | 28,085 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |